BioAge Labs, Inc. (NASDAQ:BIOA) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on BioAge Labs, with six buy ratings and one sell rating. The average 12-month price target is $36.57, well above the reported $9.59 share price.
• BioAge Labs shares have declined significantly, trading below their 50-day and 200-day moving averages and near the lower end of their $4.58–$25.95 52-week range. The company’s market capitalization is approximately $440 million.
• In its latest quarter, BioAge reported a loss of $0.58 per share, beating analyst expectations of a $0.65 loss, and generated $2.45 million in revenue. Analysts expect a full-year loss of approximately $2.45 per share.

Shares of BioAge Labs, Inc. (NASDAQ:BIOA - Get Free Report) have been given an average rating of "Moderate Buy" by the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $36.5714.

Several equities research analysts recently commented on BIOA shares. Roth Capital restated a "buy" rating and set a $25.00 target price on shares of BioAge Labs in a research report on Friday, July 31st. BTIG Research restated a "buy" rating and set a $40.00 price target on shares of BioAge Labs in a report on Monday, August 3rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioAge Labs in a research report on Tuesday, July 21st. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research note on Friday, July 31st. Finally, Needham & Company LLC cut their target price on shares of BioAge Labs from $50.00 to $35.00 and set a "buy" rating on the stock in a research note on Friday, July 31st.

Hedge Funds Weigh In On BioAge Labs

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. acquired a new stake in BioAge Labs in the 3rd quarter valued at $27,000. CWM LLC boosted its stake in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company's stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of BioAge Labs by 85.6% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company's stock valued at $54,000 after buying an additional 5,976 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of BioAge Labs in the 2nd quarter worth $64,000. Finally, Bank of America Corp DE boosted its stake in shares of BioAge Labs by 46.3% in the 3rd quarter. Bank of America Corp DE now owns 11,119 shares of the company's stock worth $65,000 after buying an additional 3,517 shares during the last quarter.

BioAge Labs Stock Performance

Shares of NASDAQ BIOA opened at $9.59 on Friday. The company's 50 day moving average price is $16.50 and its 200-day moving average price is $17.82. BioAge Labs has a 52-week low of $4.58 and a 52-week high of $25.95. The company has a market capitalization of $440.18 million, a P/E ratio of -4.03 and a beta of 0.94.

BioAge Labs (NASDAQ:BIOA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million for the quarter. Analysts forecast that BioAge Labs will post -2.45 earnings per share for the current year.

BioAge Labs Company Profile

BioAge Labs NASDAQ: BIOA is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source